Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (351-360 of 443) with videos related to

Pageof 45
Sort By:
American Journal of Hematology|November 18, 2022
Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMTMichele Wieczorek, Myriam Labopin, Luca Castagna, et al.
American Journal of Hematology|June 10, 2024
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
American Journal of Hematology|July 12, 2025
Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationYishan Ye, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
BMC Cancer|April 27, 2025
Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMTRyszard Swoboda, Myriam Labopin, Sebastian Giebel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 3, 2020
Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell TransplantationCarolina Marini, Eolia Brissot, Abdulhamid Bazarbachi, et al.
Bone Marrow Transplantation|July 8, 2026
Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMTRyszard Swoboda, Myriam Labopin, Nicolaus Kröger, et al.
Bone Marrow Transplantation|May 14, 2022
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working PartyJesus Duque-Afonso, Jürgen Finke, Myriam Labopin, et al.
Bone Marrow Transplantation|October 7, 2022
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaArnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation|April 8, 2022
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysisEduardo Rodríguez-Arbolí, Myriam Labopin, Matthias Eder, et al.
Bone Marrow Transplantation|April 12, 2023
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMTArnon Nagler, Myriam Labopin, Stephan Mielke, et al.
Pageof 45

Showing results (351-360 of 443) with videos related to

Sort By:
Pageof 45
American Journal of Hematology|November 18, 2022
Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMTMichele Wieczorek, Myriam Labopin, Luca Castagna, et al.
American Journal of Hematology|June 10, 2024
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
American Journal of Hematology|July 12, 2025
Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationYishan Ye, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
BMC Cancer|April 27, 2025
Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMTRyszard Swoboda, Myriam Labopin, Sebastian Giebel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 3, 2020
Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell TransplantationCarolina Marini, Eolia Brissot, Abdulhamid Bazarbachi, et al.
Bone Marrow Transplantation|July 8, 2026
Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMTRyszard Swoboda, Myriam Labopin, Nicolaus Kröger, et al.
Bone Marrow Transplantation|May 14, 2022
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working PartyJesus Duque-Afonso, Jürgen Finke, Myriam Labopin, et al.
Bone Marrow Transplantation|October 7, 2022
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaArnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation|April 8, 2022
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysisEduardo Rodríguez-Arbolí, Myriam Labopin, Matthias Eder, et al.
Bone Marrow Transplantation|April 12, 2023
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMTArnon Nagler, Myriam Labopin, Stephan Mielke, et al.
Pageof 45